CURACLE CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,780 KRW | +3.07% |
|
+5.51% | +61.48% |
| Sales 2022 | 3.58B 2.6M 217M | Sales 2023 | 10.29B 7.48M 624M | Capitalization | 161B 117M 9.76B |
|---|---|---|---|---|---|
| Net income 2022 | -11.41B -8.29M -691M | Net income 2023 | -11.59B -8.42M -702M | EV / Sales 2022 | 37.3 x |
| Net cash position 2022 | 23.45B 17.05M 1.42B | Net cash position 2023 | 22.41B 16.29M 1.36B | EV / Sales 2023 | 13.5 x |
| P/E ratio 2022 |
-13.7
x | P/E ratio 2023 |
-13.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.79% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.07% | ||
| 1 week | +5.51% | ||
| Current month | +6.52% | ||
| 1 month | +4.68% | ||
| 3 months | +78.69% | ||
| 6 months | +123.04% | ||
| Current year | +61.48% |
1 week
17 710.00
21 100.00
1 month
14 310.0021 350.00
Current year
9 960.0021 350.00
1 year
8 250.0021 350.00
3 years
8 250.0062 400.00
5 years
8 250.0062 400.00
10 years
8 250.0062 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kwang-Rak Park
CEO | Chief Executive Officer | - | - |
Myung-Hwa Kim
CEO | Chief Executive Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Myung-Hwa Kim
CEO | Chief Executive Officer | - | - |
Kwang-Rak Park
CEO | Chief Executive Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 18,780 | +3.07% | 280,295 |
| 25/24/25 | 18,220 | -7.56% | 406,099 |
| 24/24/24 | 19,710 | +5.74% | 1,325,053 |
| 23/24/23 | 18,640 | +2.14% | 463,985 |
| 22/24/22 | 18,250 | +2.53% | 297,313 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
Curacle Co Ltd is a Korea-based company primarily engaged in the development of therapeutics for intractable vascular and metabolic diseases. The Company researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Companyâs drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +61.48% | 189M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- A365270 Stock
